ACUTE MYELOID LEUKEMIA

This study tests a drug called ziftomenib for adults with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or KMT2A). Participants are people who cannot receive standard intensive chemotherapy. The drug works by blocking a protein called menin, which helps the can…

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can lower the chance of leukemia coming back. It includes 160 people aged 15-60 with high-risk or relapsed acute leukemia or myelodysplastic syndromes. Parti…

This study tests whether adding the drug olutasidenib to standard treatments helps more people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieve remission. About 132 adults with these blood cancers will receive either standard therapy alone …

This early-stage study tests a new drug called PLM-102 in 12 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to find the safest dose and watch for side effects. Participants will be closely monitored to see how well…

This study tests a new drug called BL-M11D1 combined with standard chemotherapy or other targeted drugs for adults with newly diagnosed acute myeloid leukemia (AML). The goal is to see if the combination is safe and helps more patients achieve remission. About 216 participants wi…

This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a targeted radiation drug (131I-apamistamab) along with standard chemotherapy and low-dose whole-body radia…

This study tests a milder chemotherapy combination (fludarabine and treosulfan) given before a stem cell transplant from a half-matched donor for older or frail adults with acute myeloid leukemia (AML). The goal is to see if this approach can help control the cancer longer while …

This study tests a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant from a half-matched donor. It includes 93 older adults (ages 55-75) with acute myeloid leukemia who are in their first remission. The goal is to se…

This early-stage trial tests a new type of immunotherapy called universal CLL1 CAR-T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy uses donor T cells engineered to find and attack AML cells while sparing …

This early-stage study tests a new drug called lonitoclax combined with azacitidine in adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy. The main goals are to find the best dose and check safety. About 66 participants will take part. Th…

This early-phase trial tests a new drug called axatilimab combined with two standard chemotherapy drugs for people with a specific, hard-to-treat type of acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and se…

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes (MDS). About 180 participants aged 15-60 will be randomly a…

This study tests whether combining different chemotherapy drugs can better eliminate leftover leukemia cells in adults with acute myeloid leukemia (AML) before they receive a stem cell transplant. About 184 participants will receive either standard treatment or one of three drug …

This study tests whether adding a new drug called pivekimab sunirine to two standard medicines (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants worldwide will …

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This study is for adults aged 18 to 65 with acute myeloid leukemia (AML) that has returned or not responded to treatment. Participants will receive a stem cell transplant from a half-matched donor, along with medicines and immune cells after transplant to try to prevent the cance…

This early-phase study tests whether adding a new drug called eganelisib to two standard AML treatments (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to prior therapy. About 48 adults will take part to find the bes…

This study tests whether a combination of two drugs (venetoclax and azacitidine) works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults with high-risk AML who are already in remission…

This study tests whether the drug interferon-α can help prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back in patients with a TP53 gene mutation who have already had a stem cell transplant. About 100 people aged 12-65 will receive interferon-α…

This study tests whether the antibiotic levofloxacin can safely lower the risk of infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. About 75 adults will be randomly assigned to take levofloxacin…

This early study tests a new approach using donor immune cells boosted by exercise to prevent or treat leukemia relapse after a stem cell transplant. About 94 people with blood cancers will receive either standard donor cells or these exercise-mobilized cells. The goal is to see …

This early-phase trial tests whether giving ruxolitinib followed by ruxolitinib plus azacitidine after a stem cell transplant can safely prevent graft-versus-host disease (GVHD) and keep acute myeloid leukemia (AML) from coming back. About 40 adults with AML in remission will tak…

This study looks at two ways of giving donor immune cells after a stem cell transplant to prevent cancer from coming back in people with hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. About 200 participants will be randomly assigned to receive donor cells eith…

This study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers (like acute myeloid leukemia or myelodysplastic syndromes). About 450 adults will be assigned to receive or not r…

This trial tests a new way to do a stem cell transplant for young adults (ages 16-55) with very aggressive acute myeloid leukemia (AML) that hasn't responded to chemo or has high-risk gene changes. It uses umbilical cord blood plus extra white blood cells (granulocytes) to try to…

This study looks at whether older or frail patients with acute myeloid leukemia (AML) can safely take a shorter course of the drug venetoclax, based on their bone marrow results on Day 14, instead of the standard longer course. About 250 participants will be randomly assigned to …

This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from returning in patients over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…

This early-phase trial tests a combination of two drugs, olutasidenib and ziftomenib, in about 20 adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds the safest dose, and the second part checks if that …

This study tests a new oral drug called revumenib in adults with certain types of acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to see if taking this pill after transplant can help prevent the leukemia from returning. About 144 participants will be…

This early-stage trial tests a drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. Participants receive the drug b…

This study tests whether adding the drug venetoclax to standard chemotherapy before and after a stem cell transplant can help prevent acute myeloid leukemia (AML) from coming back. About 244 adults with AML in first remission will receive either venetoclax or a placebo alongside …

This study tests whether dental wipes containing xylitol, a natural sugar that limits bacteria growth, can reduce bloodstream infections in children with acute myeloid leukemia (AML). About 556 children and young adults (ages 1-25) will use either xylitol wipes or plain wipes dur…

This study looks at whether medical hypnosis or virtual reality sessions can lower anxiety in adults with acute myeloid leukemia during their first round of chemotherapy. About 99 participants will be split into three groups: standard care alone, standard care plus hypnosis, or s…

This study tests a painless, non-invasive skin measurement called electrical bioimpedance (BioZ) in 25 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if BioZ results match findings from standard bone marrow biopsies. If successful, …

This study tests whether a single injection of motixafortide can help reveal leftover leukemia cells (measurable residual disease, or MRD) in the blood of people with acute myeloid leukemia (AML) who have finished their first round of chemotherapy. Ten participants will receive t…

This study will look at blood clotting problems in 80 adults newly diagnosed with acute myeloid leukemia (AML) who are about to receive strong chemotherapy. The goal is to measure changes in clotting before and after treatment to better understand bleeding risks. This is an obser…

This study will create a structured follow-up program for 400 children and young adults who have survived blood cancers like leukemia and lymphoma. The goal is to better track and manage long-term health problems that can appear years after treatment. Researchers will use an elec…

This study looks at whether less fit adults with acute myeloid leukemia (AML) are willing to let a computer randomly assign them to lower- or higher-intensity chemotherapy. The goal is to see if this approach is acceptable to patients, so future larger studies can better determin…

This study tests a new, standardized way to measure a type of immune cell called iNKT in the blood of 75 patients who have had a stem cell transplant for leukemia. The goal is to see if the levels of these cells can help predict serious complications like graft-versus-host diseas…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if using the app helps patients feel…